Cyclin D1 expression as a prognostic factor in advanced hypopharyngeal carcinoma. 1998

G Nishimura, and M Tsukuda, and L X Zhou, and S Furukawa, and Y Baba
Department of Otorhinolaryngology, Yokohama City University School of Medicine, Kanagawa, Japan.

Hypopharyngeal carcinoma (HPC) has a poor prognosis. We investigated the expression of cyclin D1 in 34 advanced HPCs, and the value of cyclin D1 expression was evaluated as a predictive marker in terms of the prognosis of HPC, compared with other clinical factors. Using immunohistochemical staining, 20 of 34 patients showed positive immunoreactivity for cyclin D1. The statistical trend of the survival rate was lower in the cyclin D1-positive patients than in the cyclin D-negative ones (p = 0.0805). The predictive factors for the survival rate were effectiveness of neo-adjuvant chemotherapy (F = 8.698) (p = 0.0066), cyclin D1 expression (F = 6.244) (p = 0.0191) and N classification (F = 5.037) (p = 0.0335). The cyclin D1-positive patients had approximately four-fold higher mortality than the cyclin D1-negative ones. These data indicate that the expression of cyclin D1, in advanced patients with hypopharyngeal carcinoma is a useful marker for prognosis.

UI MeSH Term Description Entries
D007012 Hypopharyngeal Neoplasms Tumors or cancer of the HYPOPHARYNX. Hypopharyngeal Cancer,Neoplasms, Hypopharyngeal,Cancer, Hypopharyngeal,Cancers, Hypopharyngeal,Hypopharyngeal Cancers,Hypopharyngeal Neoplasm,Neoplasm, Hypopharyngeal
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002277 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." Carcinoma, Anaplastic,Carcinoma, Spindle-Cell,Carcinoma, Undifferentiated,Carcinomatosis,Epithelial Neoplasms, Malignant,Epithelioma,Epithelial Tumors, Malignant,Malignant Epithelial Neoplasms,Neoplasms, Malignant Epithelial,Anaplastic Carcinoma,Anaplastic Carcinomas,Carcinoma, Spindle Cell,Carcinomas,Carcinomatoses,Epithelial Neoplasm, Malignant,Epithelial Tumor, Malignant,Epitheliomas,Malignant Epithelial Neoplasm,Malignant Epithelial Tumor,Malignant Epithelial Tumors,Neoplasm, Malignant Epithelial,Spindle-Cell Carcinoma,Spindle-Cell Carcinomas,Tumor, Malignant Epithelial,Undifferentiated Carcinoma,Undifferentiated Carcinomas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

G Nishimura, and M Tsukuda, and L X Zhou, and S Furukawa, and Y Baba
November 2001, Journal of surgical oncology,
G Nishimura, and M Tsukuda, and L X Zhou, and S Furukawa, and Y Baba
December 2019, Translational lung cancer research,
G Nishimura, and M Tsukuda, and L X Zhou, and S Furukawa, and Y Baba
February 1999, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery,
G Nishimura, and M Tsukuda, and L X Zhou, and S Furukawa, and Y Baba
April 2011, The Indian journal of medical research,
G Nishimura, and M Tsukuda, and L X Zhou, and S Furukawa, and Y Baba
March 2005, Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology,
G Nishimura, and M Tsukuda, and L X Zhou, and S Furukawa, and Y Baba
January 2023, Northern clinics of Istanbul,
G Nishimura, and M Tsukuda, and L X Zhou, and S Furukawa, and Y Baba
October 2008, Croatian medical journal,
G Nishimura, and M Tsukuda, and L X Zhou, and S Furukawa, and Y Baba
August 2007, Neuro endocrinology letters,
G Nishimura, and M Tsukuda, and L X Zhou, and S Furukawa, and Y Baba
June 2014, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas,
G Nishimura, and M Tsukuda, and L X Zhou, and S Furukawa, and Y Baba
August 1996, Cancer,
Copied contents to your clipboard!